Tag: Infusion schedule

Nexviazyme (avalglucosidase alfa-ngpt) is a specific enzyme replacement therapy approved for late-onset Pompe disease (LOPD) in patients one year of age and older. The standard recommendation is to administer this medication as an intravenous (IV) infusion every two weeks. This consistent administration schedule is a fundamental aspect of managing this rare genetic condition by providing a steady supply of the missing enzyme.

Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted cancer therapy that is typically administered to patients in a standardized, three-week dosing cycle. This schedule is carefully managed by healthcare providers to ensure the medication's effectiveness while monitoring for any potential side effects.